[go: up one dir, main page]

PT3093022T - Inibidores gata-3 para utilização no tratamento de asma desencadeada por th2 - Google Patents

Inibidores gata-3 para utilização no tratamento de asma desencadeada por th2

Info

Publication number
PT3093022T
PT3093022T PT150014728T PT15001472T PT3093022T PT 3093022 T PT3093022 T PT 3093022T PT 150014728 T PT150014728 T PT 150014728T PT 15001472 T PT15001472 T PT 15001472T PT 3093022 T PT3093022 T PT 3093022T
Authority
PT
Portugal
Prior art keywords
gata
inhibitors
treatment
driven asthma
asthma
Prior art date
Application number
PT150014728T
Other languages
English (en)
Inventor
Bille Joachim
renz Jonas
Original Assignee
Sterna Biologicals Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterna Biologicals Gmbh & Co Kg filed Critical Sterna Biologicals Gmbh & Co Kg
Publication of PT3093022T publication Critical patent/PT3093022T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127DNAzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT150014728T 2015-05-15 2015-05-15 Inibidores gata-3 para utilização no tratamento de asma desencadeada por th2 PT3093022T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001472.8A EP3093022B1 (en) 2015-05-15 2015-05-15 Gata-3 inhibitors for use in the treatment of th2-driven asthma

Publications (1)

Publication Number Publication Date
PT3093022T true PT3093022T (pt) 2019-11-11

Family

ID=53274335

Family Applications (1)

Application Number Title Priority Date Filing Date
PT150014728T PT3093022T (pt) 2015-05-15 2015-05-15 Inibidores gata-3 para utilização no tratamento de asma desencadeada por th2

Country Status (16)

Country Link
US (1) US10487325B2 (pt)
EP (1) EP3093022B1 (pt)
JP (1) JP2018515611A (pt)
KR (1) KR20180004816A (pt)
CN (2) CN115137827A (pt)
AU (1) AU2016264772B2 (pt)
BR (1) BR112017024394A2 (pt)
CA (1) CA2985858C (pt)
DK (1) DK3093022T3 (pt)
ES (1) ES2753436T3 (pt)
HU (1) HUE046190T2 (pt)
PL (1) PL3093022T3 (pt)
PT (1) PT3093022T (pt)
RU (1) RU2720988C2 (pt)
SI (1) SI3093022T1 (pt)
WO (1) WO2016184556A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205506A1 (en) 2016-05-24 2017-11-30 Emory University Particles with rna cleaving nucleobase polymers and uses for managing inflammatory disorders
EP3501607A1 (de) * 2017-12-22 2019-06-26 Sterna Biologicals GmbH & Co. KG Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung
EP3603617A1 (de) * 2018-07-30 2020-02-05 Sterna Biologicals GmbH & Co. KG Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung
EP3805242A1 (en) * 2019-10-07 2021-04-14 Sterna Biologicals GmbH & Co. KG Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma
US11976282B2 (en) 2020-06-23 2024-05-07 Qatar University GATA3 inhibitors for the promotion of subcutaneous fat deposition
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1117768A4 (en) 1998-08-13 2003-09-03 Johnson & Johnson Res Pty Ltd DNAZYMS AND METHOD FOR TREATING RESTENOSES
AUPP810399A0 (en) 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
IL145034A0 (en) 1999-03-05 2002-06-30 Epigenesis Pharmaceuticals Inc Method for validating/invalidating target(s) and pathways
AUPQ201499A0 (en) 1999-08-04 1999-08-26 Unisearch Limited Treatment of inflammatory and malignant diseases
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
TWI322690B (en) * 2006-05-11 2010-04-01 Flysun Dev Co Ltd Short interference ribonucleic acids for treating allergic dieases
DE102010007562A1 (de) * 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
EP2708898A1 (de) 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten

Also Published As

Publication number Publication date
US20190062737A1 (en) 2019-02-28
CA2985858A1 (en) 2016-11-24
RU2017143014A (ru) 2019-06-17
DK3093022T3 (da) 2019-11-04
JP2018515611A (ja) 2018-06-14
CA2985858C (en) 2023-10-10
SI3093022T1 (sl) 2019-12-31
CN115137827A (zh) 2022-10-04
ES2753436T3 (es) 2020-04-08
NZ736807A (en) 2024-08-30
HUE046190T2 (hu) 2020-02-28
RU2720988C2 (ru) 2020-05-15
EP3093022A1 (en) 2016-11-16
KR20180004816A (ko) 2018-01-12
AU2016264772B2 (en) 2021-09-09
WO2016184556A1 (en) 2016-11-24
US10487325B2 (en) 2019-11-26
RU2017143014A3 (pt) 2019-10-25
CN107771082A (zh) 2018-03-06
BR112017024394A2 (pt) 2018-07-24
EP3093022B1 (en) 2019-08-07
PL3093022T3 (pl) 2020-02-28
AU2016264772A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL267291A (en) Actonucleotidase inhibitors and methods of using them
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
IL259801A (en) ezh2 inhibitors and methods of using them
IL250318B (en) Protein kinase c inhibitors and methods of using them
IL267238A (en) The paranase inhibitors and their use
IL251904A0 (en) Epilimod for use in the treatment of melanoma
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
SG11201608397UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
IL254916B (en) Inhibitors and their uses
SG11201705907XA (en) Mir-92 inhibitors and uses thereof
PT3093022T (pt) Inibidores gata-3 para utilização no tratamento de asma desencadeada por th2
IL263804A (en) Wnt inhibitors for use in the treatment of fibrosis
GB201702160D0 (en) Inhibitors for use in therapy
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
ZA201803212B (en) Gelatinase inhibitors and use thereof
IL267243A (en) The paranase inhibitors and their use
GB201509977D0 (en) Dispensers and methods of use thereof
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses
GB201409466D0 (en) Urea compounds and their use as enzyme inhibitors
ZA201408464B (en) Composition for the use in treatment of asthma
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors